OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
Reza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3596-3596
Open Access | Times Cited: 17
Reza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3596-3596
Open Access | Times Cited: 17
Showing 17 citing articles:
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 40
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 40
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, et al.
JAMA Oncology (2023) Vol. 9, Iss. 11, pp. 1574-1574
Open Access | Times Cited: 35
Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, et al.
JAMA Oncology (2023) Vol. 9, Iss. 11, pp. 1574-1574
Open Access | Times Cited: 35
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo, Jixia Li, Jinxia Hu, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110417-110417
Open Access | Times Cited: 18
Ruoyu Guo, Jixia Li, Jinxia Hu, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110417-110417
Open Access | Times Cited: 18
Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy
Theivendren Panneerselvam, Selvaraj Kunjiappan, Parasuraman Pavadai, et al.
ACS Measurement Science Au (2024) Vol. 5, Iss. 1, pp. 31-55
Open Access | Times Cited: 5
Theivendren Panneerselvam, Selvaraj Kunjiappan, Parasuraman Pavadai, et al.
ACS Measurement Science Au (2024) Vol. 5, Iss. 1, pp. 31-55
Open Access | Times Cited: 5
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
Carlos R. Gil Del Alcazar, Anne Trinh, Maša Alečković, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 6, pp. 680-697
Open Access | Times Cited: 22
Carlos R. Gil Del Alcazar, Anne Trinh, Maša Alečković, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 6, pp. 680-697
Open Access | Times Cited: 22
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)
Shanshan Yang, Suya Zhao, Yixiang Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Shanshan Yang, Suya Zhao, Yixiang Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Next‐generation pathology detection of T cell–antigen‐presenting cell immune synapses in human liver allografts
Michelle A. Wood, Drew Lesniak, Alessandro Gambella, et al.
Hepatology (2022), pp. n/a-n/a
Open Access | Times Cited: 20
Michelle A. Wood, Drew Lesniak, Alessandro Gambella, et al.
Hepatology (2022), pp. n/a-n/a
Open Access | Times Cited: 20
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
Noboru Yamamoto, Takafumi Koyama, Jun Sato, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 1, pp. 109-115
Open Access | Times Cited: 4
Noboru Yamamoto, Takafumi Koyama, Jun Sato, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 1, pp. 109-115
Open Access | Times Cited: 4
Role of liposomes in chemoimmunotherapy of Breast cancer
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Pharmacological landscape of endoplasmic reticulum stress: uncovering therapeutic avenues for metabolic diseases
Ghallab Alotaibi, Abdullah Alkhammash
European Journal of Pharmacology (2025), pp. 177509-177509
Closed Access
Ghallab Alotaibi, Abdullah Alkhammash
European Journal of Pharmacology (2025), pp. 177509-177509
Closed Access
Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)
Elena Garralda, Do Youn Oh, Antoîne Italiano, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 5, pp. 544-554
Open Access | Times Cited: 9
Elena Garralda, Do Youn Oh, Antoîne Italiano, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 5, pp. 544-554
Open Access | Times Cited: 9
Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
Pere Llinàs‐Arias, Sandra Íñiguez-Muñoz, Kelly McCann, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4139-4139
Open Access | Times Cited: 17
Pere Llinàs‐Arias, Sandra Íñiguez-Muñoz, Kelly McCann, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4139-4139
Open Access | Times Cited: 17
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
Colby S. Shemesh, Yongsheng Wang, Andrew An, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 1, pp. 45-55
Open Access | Times Cited: 1
Colby S. Shemesh, Yongsheng Wang, Andrew An, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 1, pp. 45-55
Open Access | Times Cited: 1
Recent Trends and Opportunities for the Targeted Immuno-Nanomaterials for Cancer Theranostics Applications
Clyde John, Kaahini Jain, Hema Brindha Masanam, et al.
Micromachines (2022) Vol. 13, Iss. 12, pp. 2217-2217
Open Access | Times Cited: 5
Clyde John, Kaahini Jain, Hema Brindha Masanam, et al.
Micromachines (2022) Vol. 13, Iss. 12, pp. 2217-2217
Open Access | Times Cited: 5
Harmine and its derivatives: an In-depth review of antitumor mechanisms and structure-activity relationship
Taoufik Akabli, Hamid Toufik, Fatima Lamchouri
Medicinal Chemistry Research (2024)
Closed Access
Taoufik Akabli, Hamid Toufik, Fatima Lamchouri
Medicinal Chemistry Research (2024)
Closed Access
CLASSIFICATION OF BLOOD SUBSTITUTES
Safiah Syahirah Shamsul Bahrin, Siti Noor Fazliah Mohd Noor, Siti Salmah Noordin, et al.
Journal of Health and Translational Medicine (2023) Vol. sp2023, Iss. 1, pp. 261-277
Open Access
Safiah Syahirah Shamsul Bahrin, Siti Noor Fazliah Mohd Noor, Siti Salmah Noordin, et al.
Journal of Health and Translational Medicine (2023) Vol. sp2023, Iss. 1, pp. 261-277
Open Access
